Elderly patients are an unmet need in Hodgkin lymphoma

1st-line therapies in Hodgkin lymphoma

Top ASH 2025 updates in AML: redefining frontline therapy, menin inhibition, & more

The longest reported survival to date in any unselected group of patients with multiple myeloma

Follicular Lymphoma Foundation: research mission, biomarkers, and global collaboration

Personalized approaches to Hodgkin lymphoma

VMP ± Dara versus Rd ± Dara in transplant-ineligible patients with myeloma: a Phase IV trial

Phase Ib study of bleximenib plus venetoclax in AML with KMT2A or NPM1 alterations

Optimal ferritin threshold to diagnose IEC-HS following CAR T-cell therapy in R/R myeloma

Real-world barriers to treatment access in T-cell lymphoma

GOLSEEK-1 trial: golcadomide plus R-CHOP in frontline high-risk large B-cell lymphoma

Redefining high-risk myeloma in the context of upfront quadruplet therapy and ASCT

Real-world ibrutinib plus venetoclax in frontline CLL/SLL: REALITY-WW and REALITY-2 outcomes

Drivers of racial and ethnic disparities in access to frontline CLL therapy in the US

Treatment strategies for multiple myeloma progressing after upfront quadruplet therapy

Non-opioid and integrative strategies for pain management during VOC in SCD

AMPLIFY trial: how prognostic mutations impact outcomes with acalabrutinib-venetoclax in CLL

MRD trajectory and prognosis in t(11;14) multiple myeloma treated with quadruplet therapy and ASCT

The potential of bispecific T-cell engagers targeting FLT3 in AML

Validation of MRD as a surrogate endpoint in AML: ongoing research & updates from HARMONY Alliance